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Abstract
Background: Diacylglyceride acyltransferase 1 (DGAT1) is the enzyme that adds the final fatty acid on to a
diacylglyceride during triglyceride (TG) synthesis. DGAT1 plays a key role in the repackaging of dietary TG into
circulating TG rich chylomicrons. A growing amount of research has indicated that an exaggerated postprandial
circulating TG level is a risk indicator for cardiovascular and metabolic disorders. The aim of this research was to
identify a botanical extract that inhibits intestinal DGAT1 activity and attenuates postprandial hypertriglyceridemia
in overweight and obese humans.
Methods: Twenty individual phytochemicals and an internal proprietary botanical extract library were screened
with a primary cell-free DGAT1 enzyme assay that contained dioleoyl glycerol and palmitoleoyl Coenzyme A as
substrates plus human intestinal microsomes as the DGAT1 enzyme source. Botanical extracts with IC50
values < 100 μg/mL were evaluated in a cellular DGAT1 assay. The cellular DGAT1 assay comprised the analysis of 14C
labeled TG synthesis in cells incubated with 14C-glycerol and 0.3 mM oleic acid. Lead botanical extracts were then
evaluated in a parallel, double-blind, placebo-controlled clinical trial. Ninety healthy, overweight and obese participants
were randomized to receive 2 g daily of placebo or individual botanical extracts (the investigational product) for seven
days. Serum TG levels were measured before and after consuming a high fat meal (HFM) challenge (0.354 L drink/
shake; 77 g fat, 25 g carbohydrate and 9 g protein) as a marker of intestinal DGAT1 enzyme activity.
Results: Phenolic acids (i.e., gallic acid) and polyphenols (i.e., cyanidin) abundantly found in nature appeared to
inhibit DGAT1 enzyme activity in vitro. Four polyphenolic rich botanical extracts were identified from in vitro
evaluation in both cell-free and cellular model systems: apple peel extract (APE), grape extract (GE), red raspberry
leaf extract (RLE) and apricot/nectarine extract (ANE) (IC50 = 1.4, 5.6, and 10.4 and 3.4 μg/mL, respectively). In the
seven day clinical trial, compared to placebo, only GE significantly reduced the baseline subtracted change in
serum TG AUC following consumption of the HFM (AUC = 281 ± 37 vs. 181 ± 30 mg/dL*h, respectively; P = 0.021).
Chromatographic characterization of the GE revealed a large number of closely eluting components containing
proanthocyanidins, catechins, anthocyanins and their secondary metabolites that corresponded with the
observed DGAT1 enzyme inhibition in the cell-free model.
Conclusion: These data suggest that a dietary GE has the potential to attenuate postprandial
hypertriglyceridemia in part by the inhibition of intestinal DGAT1 enzyme activity without intolerable side effects.
Trial registration: This trial was registered with ClinicalTrials.gov NCT02333461
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Background
Overweight and obese conditions develop as a result of
chronic energy imbalance, arising when energy input ex-
ceeds energy expenditure. Sedentary lifestyle and the
availability of inexpensive, highly palatable, energy-dense
foods that are high in fat and refined carbohydrates are
major drivers of the global obesity epidemic [1]. These
foods displace healthier options, such as fruits and vege-
tables, from the diet and promote storage of excess calo-
ries as body fat. Fruits and vegetables have long been
known to be important sources of vitamins, minerals
and fiber and are increasingly recognized for the com-
plex and diverse collection of health-promoting phyto-
chemicals they contribute to the diet [2].
Elevated blood triglyceride (TG), another conse-
quence of an eating pattern that is high in fat and re-
fined carbohydrate, is recognized as an independent
risk factor for conditions such as metabolic syndrome,
type II diabetes and cardiovascular disease [3]. In
addition, there is growing evidence that postprandial
TG levels strengthens the assessment of metabolic and
cardiovascular risk [4–7]. Zilversmit [8] first reported
that postprandial hyperlipidemia could be a significant
metabolic factor contributing to the development of
atherogenesis. He proposed that postprandial TG rich
chylomicrons are as atherogenic as circulating low-density
lipoprotein cholesterol (LDL-C), and emphasized the need
for studies that address this phenomenon. Research
around postprandial hypertriglyceridemia continues to be
a topic of great interest [4–7, 9–12]. In fact, postprandial
TG levels have been reported to be more predictive of
cardiovascular risk compared to fasting TG [9, 13]. The
circulating TG levels in response to a meal are dependent
on many variables including total amount and type of
dietary fats, fasting TG levels, gastric emptying, intestinal
break down, absorption and secretion of TG and systemic
catabolism. Given humans spend a significant amount of
time in the postprandial state, the chronic systemic expos-
ure of postprandial hypertriglyceridemia could contribute
to multiple metabolic disorders via multiple mechanisms
[14–21]. Therefore, nutritional approaches that target
postprandial hypertriglyceridemia in response to a fatty
meal is mechanism that could have meaningful impact on
cardiovascular and metabolic risks and health.
Diacylglycerol acyltransferase 1 (DGAT1) in entero-
cytes is a key enzyme involved in the assembly of TG
from dietary fatty acids [22]. In the postprandial state,
intestinal DGAT1 generated TG are secreted into the
lymphatic system, mainly as chylomicron particles, and
then enter the blood circulation via the thoracic duct
(Fig. 1). DGAT1-deficient (Dgat1−/−) mice are resistant
to high fat diet-induced obesity due in part to an in-
crease in systemic energy expenditure induced by body
heat loss [23]. It was later reported that intestinal only
DGAT1 deficiency could reproduce many of the high fat
diet induced phenotypes of the Dgat1−/− mouse [24]. In
addition, intestinal only expression of DGAT1 abolished
the anti-obesity phenotypes of Dgat1−/− mouse while
on a high fat diet [25]. These animal studies lead to the
pharmaceutical development of intestinal DGAT1 inhib-
itors as a mechanistic approach to mitigate metabolic
risks associated with elevated postprandial TG levels [12,
26, 27]. These and other reports suggest that delaying
and decreasing postprandial circulating TG levels with
intestinal DGAT1 inhibition could facilitate the improve-
ment of metabolic and cardiovascular risks and mainten-
ance of health [22, 24, 28–31]. However, a hurdle facing
pharmaceutical inhibitors thus far has been the compounds
are so selective and potent that the gastrointestinal side ef-
fect profiles, like nausea, diarrhea and vomiting are not tol-
erated [12]. Therefore, nutritional strategies targeting
postprandial TG levels via DGAT1 inhibition without in-
tolerable side effects could have meaningful impact on car-
diovascular and metabolic risks and health.
We are not aware of any published prospective hu-
man studies that provide evidence for a botanical inhibitor
of intestinal DGAT1 activity indicated by measuring
serum TG during a high fat meal (HFM). The aim of this
research was to identify a botanical extract that inhibits
intestinal DGAT1 activity and attenuates postprandial
hypertriglyceridemia in overweight and obese humans.
This report presents in vitro and in vivo evidence support-
ing inhibition of intestinal DGAT1 activity via a botanical
extract that may have the potential to improve metabolic
imbalance related to postprandial hypertriglyceridemia.
Methods
Clinical trial methodology
The randomized, double-blind, placebo-controlled clin-
ical trial was approved by the New England Institutional
Review Board (Wellesley, MA, USA) and was conducted
in compliance with the Declaration of Helsinki and the
International Conference on Harmonization Guidelines.
Informed consent to participate in the research study
was obtained from all study participants using an IRB-
approved consent form (NEIRB # 12–103). The study
was conducted from May through August, 2012 at Radi-
ant Research, Chicago, IL.
A total of 158 healthy overweight and obese individ-
uals were screened based on medical history, vital signs,
physical exam, height/weight, concomitant medication
use, serum chemistry, hematology and lipid panel as well
as a urine pregnancy test for females of childbearing age.
Participants were excluded if they had a fasting TG >
200 mg/dL or any abnormal biochemical value deemed
to be clinically significant by the Principal Investigator.
Women were excluded if they were pregnant or lactating
or were of child bearing age and unwilling to use birth
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control. The exclusion criteria included an alcoholic bev-
erage intake > 14 drinks per week and history of gastric
bypass or other surgery to physically alter the gastro-
intestinal tract. Concomitant use of medications for
blood pressure, coagulation disorders, high cholesterol,
gastroesophageal reflux, or any medication with vaso-
constricting properties such as serotonin reuptake inhib-
itors or monoamine oxidase inhibitors was an additional
exclusion criteria.
Subjects were also excluded if they had consumed an-
tibiotics in the previous week, dietary supplements (e.g.
vitamins, minerals and herbal products, including herbal
drinks) within one week, fish oil supplements or con-
sumption of fatty fish more than once per week within
eight weeks of the trial. Those who were eligible to par-
ticipate were instructed to maintain their normal diet
and physical activity pattern throughout the duration of
the study.
Investigational product (Botanical Extracts)
The investigational product doses were packed in opaque
two piece hard shell capsules. Each capsule had a fill weight
of 333 mg and contained either 100 % extract or placebo.
The placebo was comprised of silicified microcrystalline
cellulose, magnesium stearate, modified cellulose gum, sili-
con dioxide, dextrose, corn starch and caramel color. Each
qualified participant received one bottle of investigational
product that contained placebo, apple peel extract (APE),
grape extract (GE), red raspberry leaf extract (RLE) or apri-
cot/nectarine extract (ANE). See Table 1 for botanical ex-
tract details. Participants were instructed to ingest the
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Fig. 1 Role of DGAT1 in the assimilation of dietary TG into circulating TG rich chylomicrons (CM). Dietary TG are first broken down into
monoacylglycerides (MG) and fatty acids (FA) by a host of pancreatic lipases. MG and FA are then absorbed into the small intestinal
enterocytes and repackaged into diacylglyercides (DG) by monoacylglyceride acyltransferase transferase. DGAT1 then acylates the DG into TG (yellow
circles), which are incorporated into CM and secreted into the lymphatic circulation then enter the blood circulation via the thoracic duct
Table 1 Botanical extract information
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2 g/d) with the morning meal for seven days. Participants
returned their bottle of investigational product at the final
study visit.
Clinical trial procedures
Ninety participants were randomly assigned in blocks
of five to one of the five test groups. The test groups
within each block were allocated using a random
number generator (Statistical Analysis Program, Cary,
NC). The randomization codes were kept at a separate
location in the Quality Assurance Department of Radiant
Development.
Participants were instructed to fast for 12 h and
refrain from strenuous physical activity the morning of
each study day (Day 1 and 7). A standardized high fat
meal (HFM) drink/shake containing 77 g fat, 25 g
carbohydrate, and 9 g protein (Table 2) was administered
over a 15 min period at baseline (day 1) and following one
week (day 7) of placebo or investigational product. The
HFM composition was similar to the recommendations
reported by Kolovou et al. [32]. At the final study day (day
7), the final dose of the placebo or investigational product
was consumed 10 min before the time zero blood draw
and consumption of the HFM. On both study days, blood
was drawn via standard venipuncture immediately before
and 2, 4, and 6 h after consuming the HFM.
Compliance was evaluated by participant interview and
counting the investigational product capsules returned to
the clinic at final study day. Non-compliance was defined
as consumption of <80 % of the scheduled intake of inves-
tigational product. Due to the short intervention period,
participants with compliance below this threshold were
removed from the study efficacy analysis. Figure 2 details
the clinical trial participant flow.
Safety and tolerability were assessed by measuring
changes in serum chemistry, hematology, vital signs,
body weight and reported adverse events.
Outcome variables
The primary outcome variable was serum TG levels over
a 6 h time period following consumption of a standardized
HFM. Serum total cholesterol (TC), high-density lipopro-
tein cholesterol (HDL-C) and TG were measured on the
Siemens ADVIA 1800, and low-density lipoprotein choles-
terol (LDL-C) was calculated by the Friedewald equation:
LDL-C = (Total Cholesterol) – (HDL-C) – (very low-
density lipoprotein (triglycerides/5)) [33].
Cell-free DGAT1 assay
A cell-free DGAT1 assay was established using a human
small intestinal microsomal preparation (BD Biosciences)
as the enzyme source, and dioleoyl glycerol and palmito-
leoyl Coenzyme A (CoA) as substrates (Sigma). Dioleoyl
glycerol was dissolved in DMSO and diluted to 600 μM
with 175 mM Tris–HCl and 100 mM MgCl2 (Tris/MgCl2)
buffer. Palmitoleoyl CoA was dissolved in1.5 % acetone
water solution (Fisher Scientific) to 150 μM. Microsomes
were diluted to 25 μg/mL with 3.5 mg/mL BSA in Tris
MgCl2 buffer. To a 1.5 mL tube, 67 μL of each palmito-
leoyl CoA s and dioleoyl glycerol solutions (1:1 ratio) were
added and the reaction was initiated by the addition of
67 μL of microsomes. The reaction was incubated in a
37 °C water bath for 60 min. The reaction was stopped by
the addition of 1 mL of extraction solvent (isopropanol:di-
chloromethane (1:1 v/v) with 2.4 % formic acid) contain-
ing 1 μg/mL internal standard (glyceryl triolein, Sigma) to
each tube and mixed by vortexing. The tubes were centri-
fuged at 10,000Xg for 3 min. 500 μL of the bottom phase
was filtered through a Millex-HV syringe driven filter unit
with tube outlet (PVDF @ 0.45 μm, Millipore) and trans-
ferred to LC-MS vials (12x32 mm glass screw neck, preslit
cap & PTFE/silicone septa, Waters). Phytochemicals
(Sigma), botanical extracts and positive control were di-
luted in DMSO and added to the reaction with the sub-
strates at the desired concentration. The DGAT1 inhibitor
A922500 (Tocris) was used as positive control at a con-
centration of 40 nM.
LC-MS analysis
Refer to Table 3 for the mobile phase program. Solvent
A: 0.1 % ammonium acetate in water; Solvent B: 0.1 %
acetic acid in acetonitrile; Solvent C: 0.1 % acetic acid in
isopropanol; all solvents were from Fisher Scientific.
Injection volume: 10 μL. Column: Acquity BEH C18
1.7 μm, 2.1 x 50 mm. Effluent from the column was di-
rected to the electrospray source of the mass spectrom-
eter. Electrospray conditions: positive ion mode; cone
voltage: 50 eV; desolvation temperature: 450 °C; source
temperature: 140 °C; nebulizer gas flow: 800 L/h; cone
gas flow: 10 L/h. The mass spectrometer was operated at
20,000 resolving power and scans from m/z 100–1200
were acquired with a cycle time of 0.25 s. Selected ion
chromatograms were plotted for the following: m/z 875
representing the ammoniated molecular ion for triacyl-
glycerol reaction product containing 2 oleic acid and 1
palmitoleic acid moieties (C18:1/C18:1/C16:1); m/z 903
for the ammoniated molecular ion of glyceryl triolein









Dean’s Whipping Cream 66 0 0 594
Eddy’s Grand Vanilla Ice Cream 11 24 3 202
Amazing Egg 0 1 6 28
Total 77 25 9 824
All ingredients were placed in a blender and mixed. Fat = 83.5 %;
Carbohydrate = 12.0 %; Protein = 4.4 %. Each shake = 0.354 L (12 oz)
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(C18:1/C18:1/C18:1) internal standard. Quantification
was determined based on area counts of the product
relative to the internal standard.
Cellular DGAT1 assay
Three different cell lines, human colorectal (HT-29),
human embryonic kidney (HEK293H) and human hepatic
(HEPG2) were screened for the presence of both DGAT1
and DGAT2 protein. The HEK293H cell line contained
DGAT1 and little to no DGAT2 protein (Additional file 1:
Figure S1), therefore, a cellular DGAT1 assay was estab-
lished in HEK293H cells to measure the synthesis of TG.
HEK293 cell line has previously been reported to contain
only DGAT1 and not DGAT2, and has been validated as an
in vitro model to determine TG synthesis via DGAT1 [34].
The DGAT1 activity was determined by measuring the
incorporation of [14C]-glycerol (1 μCi/mL, Perkin-Elmer)
into [14C]-TG during a 5 h incubation with 0.3 mM oleic
acid/BSA in HEK293H cells. Cells were plated in 12-well
culture plates at 45,000/cm2, high glucose Dulbecco
modified eagle medium (DMEM) supplemented with
10 % (v/v) fetal bovine serum (HyClone), 100 U/mL
penicillin and 100 μg/mL streptomycin (Life Technologies)
and allowed to adhere overnight in a humidified
atmosphere with 5 % CO2 at 37 °C. Medium was then
changed to serum-free DMEM, and vehicle, positive
control (A922500) or botanical extracts were added and
pre-incubated with the cells for 30 min prior to stimu-
lating TG synthesis with oleic acid. After 5 h of treat-
ment, cells were harvested with cold phosphate
buffered saline. Cellular lipids were then extracted with
chloroform:methanol (1:2 v/v) and centrifuged. The
upper phase was aspirated and the organic phase was
dried under nitrogen. Lipids were solubilized with a
small amount of chloroform containing a TG standard
(Perkin-Elmer) and separated by TLC using toluene/
chloroform/methanol mobile phase. Lipid species were
identified by iodine vapor and compared to standards.
Silica gel spots corresponding to lipid species were
scraped into scintillation vials and the incorporated
radioactivity was quantified using a MicroBeta TriLux
(Perkin-Elmer). All cellular, radiolabeled DGAT1 assay
experiments were conducted at Zen-bio Inc. (Research
Triangle Park, NC).
Bioassay directed fractionation (BDF) of GE
GE was prepared at a concentration of 50 mg/mL in
Optima™ LCMS grade water and filtered using a What-
man 25 mm, 0.45 micron GD/X syringe filter (Fisher
Scientific, Pittsburgh, PA) into 1.5 mL HPLC autosam-
pler vials for analysis. The injection volume was 10 μL/
run, providing 500 μg of GE extract per injection. Chro-
matographic separation of phytochemicals in the diluted
extract was performed on a Acquity UPLC-H chromato-
graph equipped with a photodiode array detector (PDA)
and XBridge Shield RP18 (5 μm, 4.6 x 250 mm) column
(Waters Corp, Milford, MA). The mobile phase solutions
used for gradient separation were prepared with Optima™
Fig. 2 Clinical trial participant flow
Table 3 Liquid chromatography mobile phase program
Time (min) Flow rate
(mL/min)
Solvent A (%) Solvent B (%) Solvent C (%)
0 0.4 50 50 0
5 0.4 0 50 50
7 0.4 0 50 50
8 0.4 50 50 0
10 0.4 50 50 0
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LCMS grade solvents (Fisher Scientific, Pittsburgh, PA) as
follows: A, 0.1 % acetic acid in water and B, 0.1 % acetic
acid in acetonitrile. The mobile phase gradient (A:B), at
ambient temperature and a flow rate of 0.8 mL/min, was
initially set at 95:5 and linearly changed to 0:100 from 0 to
30 min, held for 2 min, and then returned to initial condi-
tions at 32.1 min and held until 35 min. UV-visible data
were acquired from 210 – 800 nm at a 1.2 nm resolution
using a Waters Acquity PDA eLambda detector.
The effluent was split 10:1 after the PDA detector,
with the majority going to a fraction collector configured
for 96 well plates with 2 mL well volume. Fractions were
collected at 20 s intervals for 32 min. A total of 4 injec-
tions per collection plate was performed, providing ap-
proximately 1.8 mg of GE extract per plate. The plates
were frozen at −80 °C overnight, and the solvent subse-
quently removed by freeze drying. The dried sample
plates were sealed and stored dry at −20 °C until assayed
in the cell-free DGAT1 assay.
The remaining effluent was directed to a Synapt G2
QTOF mass spectrometer (Waters Corp, Milford,
MA) equipped with an electrospray ion source and op-
erated at 25 V cone voltage. Accurate mass spectra
were collected in separate runs for both positive and
negative ions, using Leu-enkephalin as a mass marker.
Data were collected from m/z 100–1200 at 0.5 s/
spectrum. Alternating spectra were collected at 0 eV
and 20 eV collision energy per cycle, with argon used
as the collision gas in the transfer cell (MSe mode).
Mass spectra, UV spectra and bioassay responses for
fractions were time aligned for identification of phyto-
chemicals corresponding to the observed DGAT1 en-
zyme inhibition.
Statistical methods
Dose response curves for the cell-free DGAT1 assay
were fitted with a log (inhibitor) vs. response, variable
slope (four parameters) equation. Cellular DGAT1 assay
data is shown as mean ± standard error of mean (SEM)
and was analyzed by two-way ANOVA with Bonferroni's
multiple comparison test. The primary outcome variable,
serum TG level, is presented as mean ± SEM of baseline
(fasting) subtracted change in serum TG after the HFM
challenge. Area under the curve (AUC) was determined
using the trapezoidal method. Comparisons between
groups were made using unpaired t-test with Welch’s
correction. A significant effect of investigational product
was defined as P < 0.05. All statistical analyses were done
using Prism-Graph Pad Software (San Diego, CA).














































Fig. 3 Percent DGAT1 enzyme inhibition and IC50 values for single phytochemicals in the cell-free assay. Twenty individual phytochemicals were
screened through the cell-free DGAT1 enzyme assay. Six of the twenty phytochemicals were dose dependent inhibitors of DGAT1 enzyme activity
(IC50 ranged from 0.667 to 8.60 μM, compared to A-922500 = 40nM) and all were phenolic acids or polyphenols. Results are the mean of duplicates
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Results
In vitro DGAT1 screening
We first screened a panel of 20 phytochemicals,
mostly polyphenols and phenolic acids (Apigenin,
Astilbin, Catechin, Cyanidin Chloride, Dihydrokaemp-
ferol, Epigallocatechin Gallate (EGCG), Ellagic Acid,
Formononetin, Gallic Acid, Guggulsterone, Kaempferol,
Icariin, Luteolin, Naringenin, Paeoniflorin, Punicalagins,
























































































Fig. 4 Percent DGAT1 enzyme inhibition and IC50 values for the four lead botanical extracts. a APE, GE, RLE and ANE exhibited dose responsive inhibition
of DGAT1 enzyme activity in the cell-free assay. The IC50 values ranged from 1.41 to 10.4 μg/mL and 17.1 ng/mL for A-922500. Results are the mean of
triplicates. b The cellular DGAT1 assay was comprised of adding [14C]-glycerol to label newly synthesized TG and 0.3 mM oleic acid/BSA to stimulate DGAT1
activity. All botanical extracts and A-922500 inhibited oleic acid induced DGAT1 enzyme activity as measured by 14C label TG levels. GE was statistically
more potent than APE, RLE and ANE, defined as greatest inhibition at the lowest dose (100 μg/mL) (Two-way ANOVA with Bonferroni's multiple
comparisons test; P< 0.001). Result are the mean ± SEM (n= 3). Different letters, within each dose, indicate statistically significant
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Orientin, Sparteine, Taxifolin and trans-Resveratrol) in the
cell-free DGAT1 assay to aid in the selection of prospect-
ive botanical extracts for screening. Phytochemicals with
≥50 % DGAT1 inhibition at 50 μM were further examined
in titration experiments. Six phytochemicals were dose
dependent inhibitors of DGAT1 enzyme activity (Fig. 3)
and all were polyphenols or phenolic acids (data not
shown for remaining fourteen phytochemicals). The IC50
values ranged from 0.667 to 8.60 μM compared to 39.9
nM for the synthetic inhibitor A922500.
Botanical extracts from an internal, proprietary botan-
ical extract library were selected based on their predicted
presence of the polyphenolic inhibitors presented in
Fig. 3, and screened through the cell-free DGAT1 assay.
Four lead botanical extracts emerged from the library
screening (Fig. 4): 1) apple peel extract (APE); 2) grape
extract (GE); 3) red raspberry leaf extract (RLE); 4) apri-
cot/nectarine extract (ANE) with IC50 values in cell-free
assay of 1.4, 5.6, 10.4 and 3.4 μg/mL, respectively
(Fig. 4a). In the cellular DGAT1 assay, all extracts inhib-
ited TG synthesis ≥ 50 % at 100 and/or 300 μg/mL.
While all botanical extracts were effective in this cellular
assay, the GE was the most potent (greatest inhibition at
the lowest dose) with APE and RLE having equally po-
tency, and ANE the least. (Fig. 4b, P < 0.001).
Clinical trial
Participant flow through the study protocol is outlined
in Fig. 2. Ninety participants were randomized into 5
test groups: Placebo, APE, GE, RLE and ANE (n = 18/
group). Eighty-one participants completed the trial per
protocol and Table 4 shows the day 1 characteristics of
these participants. There were no significant differences
in age, body mass index (BMI) or fasting, TC, LDL-C,
HDL-C or TG at baseline between groups. Gender was
not balanced across the test groups.
No placebo or investigational product related changes
were observed in vital signs, serum chemistry or
hematology parameters (data not shown). Nineteen study
participants experienced an adverse event (AE) considered
to be potentially related to placebo or investigational
product. All of these AE were graded as mild and did not
impact study participation (Additional file 2: Table S1).
Diarrhea, potentially related to fat malabsorption, was not
reported by any subject.
There was no significant difference across all groups
in the baseline (fasting) subtracted change in serum TG
AUC after the HFM challenge at day 1 (data not shown).
After seven days of placebo or investigational products,
only the GE significantly impacted the baseline sub-
tracted change in serum TG levels following the HFM
challenge compared to placebo. GE significantly reduced
the 2 h (P = 0.014) and 4 h (P = 0.029) baseline sub-
tracted change in serum TG compared to placebo
(Fig. 5a). This translated into a significant reduction in
the AUC (Fig. 5b; P = 0.021). No significant differences in
fasting TC, LDL-C, HDL-C or TG were seen after seven
days of placebo or investigational product (Table 4).
Bioassay-directed fractionation (BDF) of GE
In efforts to identify potential bioactive phytochemicals
from GE, we chromatographically fractionated GE into a
96-well plate. Fractions were subsequently screened
through the cell-free DGAT1 enzyme assay. Chromato-
graphic characterization of GE revealed a large num-
ber of closely eluting components containing primarily
Table 4 Day 1 and day 7 characteristics of participants completing the trial per protocol
Characteristics Test Day Placebo APE GE RLE ANE
N (Male/Female) 17 (9/8) 15 (7/8) 15 (6/9) 17 (6/11) 17 (11/6)
Age (years) 46.7 ± 9.9 47.0 ± 9.3 52.7 ± 12.6 46.8 ± 8.2 48.4 ± 9.0
Body Weight (kg) 1 90.8 ± 14.7 91.0 ± 10.4 88.3 ± 15.1 86.3 ± 13.6 87.9 ± 9.7
7 90.8 ± 14.7 91.1 ± 10.7 88.0 ± 15.3 86.3 ± 13.6 88.0 ± 9.6
BMI 1 30.2 ± 3.9 32.0 ± 1.8 30.8 ± 2.9 30.8 ± 3.5 30.4 ± 3.5
7 30.1 ± 3.9 32.0 ± 1.9 30.7 ± 3.0 30.5 ± 3.4 30.4 ± 3.5
Total Cholesterol (mg/dL) 1 206 ± 41 183 ± 30 190 ± 46 196 ± 34 200 ± 46
7 195 ± 44 170 ± 25 175 ± 35 191 ± 31 184 ± 35
LDL-C (mg/dL) 1 135 ± 42 116 ± 30 115 ± 42 123 ± 34 133 ± 43
7 129 ± 43 107 ± 25 105 ± 29 117 ± 34 119 ± 35
HDL-C (mg/dL) 1 50.3 ± 18.1 51.0 ± 17.2 58.7 ± 17.2 57.8 ± 17.7 50.1 ± 12.5
7 48.2 ± 19.4 46.3 ± 13.5 55.4 ± 19.8 54.8 ± 19.2 46.8 ± 11.2
TG (mg/dL) 1 97.5 ± 39.8 96.7 ± 39.8 101.7 ± 38.7 102.3 ± 35.8 111.1 ± 46.8
7 95.8 ± 36.2 94.7 ± 26.4 90.3 ± 23.8 102.1 ± 57 103.8 ± 40.4
There were no statistically significant differences in any of the measured anthropometric or serum lipids between groups at day 1 or at day 7. Results
are Mean ± SD
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proanthocyanidins, catechins, anthocyanins and other
polyphenols based on mass spectral and UV-visible
data (Fig. 6a, b). The relative amount of DGAT1 en-
zyme inhibition (right side X-axis) for the fractions
paralleled chromatographic abundance of components
in the GE (left side X-axis). These data suggest that there
are multiple polyphenols in GE that could be contributing
to the inhibition of DGAT1 enzyme activity. Table 5 lists
ten polyphenols that were identified based on accurate
mass and UV–vis spectra data. Peaks 3–9 (malvidin-
3-glucoside, procyanidin B1, catechin, procyanidin B2,
epicatechin, procyanidin C1 and syringic acid, respect-
ively) corresponded in retention time with fractions
that inhibited DGAT1 enzyme activity by greater than
50 % in the cell-free assay (Fig. 6a, b). While the phy-
tochemicals co-elute at the time corresponding to the
observed DGAT1 enzyme inhibition, they were not
necessarily solely responsible for the inhibition of that
peak. This is due to the fact there are likely many
unresolved and unidentified phenolic acids and poly-
phenols that are co-eluting during the 9–16 min re-
tention time frame. Therefore, this unique mixture,
and one single phytochemical, is likely responsible of
the observed efficacy.
Discussion
The circulating TG levels in response to a HFM chal-
lenge has been validated in both animal and human
studies to be a method of examining intestinal DGAT1
activity [25, 27, 35–38]. Here we report the first demon-
stration in vitro and in humans that a GE inhibits intes-
tinal DGAT1 as measured by the change in serum TG
following a HFM challenge. Seven days of dietary GE re-
sulted in a significant reduction in the serum TG AUC
following the HFM compared to placebo. This effect was
unique to GE, as no significant efficacy was observed in
the three other investigational products (APE, RLE and
ANE) examined in this study.
Intestinal DGAT1 plays a major role in the post-
prandial TG response by regulating enterocyte TG
synthesis and secretion [22, 35, 39]. Intestinal DGAT1
is positioned at a site that makes it a good candidate
for impacting the postprandial TG response. Pharma-
cological inhibitors of DGAT1 have been shown to ef-
fectively reduce the postprandial TG response to an
HFM challenge [36, 37, 40, 41], but not without significant
and intolerable gastrointestinal side effects in humans like
nausea, diarrhea and vomiting. This indicates that intes-
tinal DGAT1 is a good target to reduce postprandial TG
levels. However, the gastrointestinal side effects due to the
high selectivity and potency of pharmaceutical DGAT1 in-
hibitors has limited their full development. Therefore, if
dietary interventions could reduce the chronic sys-
temic exposure of postprandial hypertriglyceridemia by
modulating, in part, intestinal DGAT1 activity without
significant and intolerable gastrointestinal side effects,
this could be a potential dietary strategy to improve
multiple cardiovascular and metabolic risks linked to
postprandial hypertriglyceridemia.













































































Fig. 5 Baseline (fasting levels) subtracted change in serum TG levels
following a HFM challenge after seven days of placebo or investigational
product. a Baseline subtracted serum TG response over a 6 h period. GE
significantly reduced the serum TG levels at 2 h (p= 0.014) and 4 h (p
= (0.029) after the HFM compared to placebo. b AUC for the baseline
subtracted serum TG was also significantly reduced by seven days of
dietary GE (p= 0.021). Fasting serum TG= 95.8 ± 8.8; 94.7 ± 6.8; 90.3 ± 6.2;
102.1 ± 13.8; 103.8 ± 9.8 mg/dL, for placebo, APE, GE, RLE and ANE,
respectively. Results are mean ± SEM. Comparisons between placebo
and investigational product test groups were made using unpaired t-test
(* P< 0.05)
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Grapes in a variety of forms have been reported to
provide multiple cardiovascular health benefits [42, 43].
These health benefits have been associated with numer-
ous mechanisms of action [42, 44, 45], and the unique
phytochemical groups present in grapes such as simple
phenolics, flavonoids, anthocyanins, stilbenes and
proanthocyanidin have been reported to be responsible
for these health benefits [42, 46–49]. On a broader clari-
fication, all these phytochemical groups belong to the
polyphenol class of phytochemicals. Some of these poly-
phenols are derived from specific components of the
grape (i.e., stilbenes in skin, anthocyanins in flesh or
proanthocyanidins in seeds) and are the most important
class of bioactive compounds in grapes. Grape is one of
Fig. 6 Cell-free DGAT1 inhibition from chromatographic fractionation of GE with overlay of the corresponding LC-MS and LC-UV chromatograms. a
The LC-MS chromatogram was generated using base peak index utility to differentiate major compounds. b The LC-UV chromatogram represents the
sum of all wavelengths to better show the complex mixture and abundance of phytochemicals in the GE extract. DGAT1 enzyme inhibition (right side
x-axis) correlates with the LC-UV pattern and abundance (left side x-axis), showing that multiple phytochemicals in the GE extract are responsible for
the observed inhibition. Identities of numbered peaks are given in Table 5
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the richest sources of polyphenols among fruits and over
500 phytochemicals have been identified [50]. Therefore,
the wide range of health benefits and pleiotropic effects
of grapes and grape products on human health is likely
due to the unique phytochemical profile [50–52]. We
have identify several of these polyphenols as potential
bioactives inhibiting DGAT1 enzyme activity.
The GE used in this study was a highly concentrated
extract (8000:1 extraction ratio) of grape pulp, skin
and seeds that is 75 % and 50 % by weight polyphenols
and oligomeric proanthocyanidins (OPC), respectively
(see Table 1). The BDF data suggests there are mul-
tiple types of polyphenols (e.g., proanthocyanidins,
catechins and anthocyanins) that are contributing to
DGAT1 enzyme inhibition (Fig. 6 and Table 5). Inter-
estingly, the APE, RLE and ANE also contain polyphe-
nols, yet no significant in vivo efficacy was observed.
This is likely due to various factors including the dif-
ferent types, absolute amounts and mutual ratios of
polyphenols as they are typically more active when
existing as a mixture, rather than in individual forms
[53]. Other factors such as intestinal absorption, hy-
drolysis by small intestine enzymes and/or bacterial
modification could have influenced the potential in
vivo efficacy of the polyphenols [54–56]. Based on the
compositional information in Table 5 and our BDF
data, it is likely that the unique profile, ratio and
amounts of anthocyanin metabolites and OPC in the
GE are involved with the observed in vivo effect, as
these polyphenols are abundant in grapes but not in
the other three botanical extracts.
We report several lines of evidence supporting the
idea that GE lowers postprandial TG, in part, via inhib-
ition of intestinal DGAT1. To support this MOA, we
used a cell-free DGAT1 enzyme screening assay in
which DGAT1 activity was derived from human intes-
tinal microsomes, and then employed MgCl2 to select-
ively inhibit any DGAT2 activity present. Secondary
confirmation of inhibition was provided by using a cell-
based assay in which the cellular model did not express
DGAT2 [34]. In vitro experiments therefore reflect only
inhibition against DGAT1 enzyme activity and not
DGAT2. This is relevant since only DGAT1, but not
DGAT2 enzyme, has been reported to be present in hu-
man small intestine [39, 57, 58]. Finally, clinical assess-
ment of functional activity relied on circulating TG levels
in response to a HFM challenge which is a validated
model and biomarker to examine intestinal DGAT1 en-
zyme activity. In this model, pharmacological inhibition of
DGAT1 in both rodents and humans results in reduced
AUC of circulating TG and increased time to peak plasma
TG following a HFM challenge [27, 35, 37, 38, 41]. This
postprandial TG profile is similar to results observed in
our clinical trial.
It is possible that additional mechanisms and targets
could have been affected by the GE that in part contributes
to the reduction in the HFM induced hypertriglyceridemia.
Mechanisms involved in controlling the rate of gastric
emptying may have been impacted via gut derived hor-
mones [59] and/or directly or indirectly by inhibition of
intestinal DGAT1 activity [35]. GE may have inhibited
other intestinal TG assimilation acyltransferase enzymes
(i.e., MGAT1, 2) or metabolic pathways that occur prior to
the DGAT1 reaction (i.e., luminal absorption and entero-
cyte transport). In addition, an effect on chylomicron as-
sembly, transport into the circulation and systemic
catabolism cannot be completely ruled out.
Conclusion
Our research has led to the identification of a dietary GE
that inhibits DGAT1 activity in vitro and is the first
clinical study to show a reduction in postprandial TG re-
sponse to a HFM in overweight and obese humans at a
dose that would be difficult to achieve in the diet with
whole grapes. These data suggest that a dietary GE has the
potential to provide safe and significant attenuation of
high fat diet driven hypertriglyceridemia via a mechanism
that may include inhibition of intestinal DGAT1 activity.
These results merit further clinical investigation and
characterization of bioactive phytochemicals unique to the
whole GE. Therefore, we are conducting a longer term
clinical study with the GE in a more diverse population
and are further characterizing potential bioactives.
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